Fed. Circ. Judge Probes 'Possible Mischief' In Biosimilar Law

By Britain Eakin (June 3, 2020, 9:57 PM EDT) -- A Federal Circuit judge questioned a lower court's decision allowing Amgen Inc. to launch a biosimilar of Genentech's blockbuster cancer drug Avastin, suggesting at a Wednesday hearing that the trial court's interpretation of the law could allow biosimilar makers to game the federal drug licensing system and skirt infringement claims....

Law360 is on it, so you are, too.

A Law360 subscription puts you at the center of fast-moving legal issues, trends and developments so you can act with speed and confidence. Over 200 articles are published daily across more than 60 topics, industries, practice areas and jurisdictions.


A Law360 subscription includes features such as

  • Daily newsletters
  • Expert analysis
  • Mobile app
  • Advanced search
  • Judge information
  • Real-time alerts
  • 450K+ searchable archived articles

And more!

Experience Law360 today with a free 7-day trial.

Start Free Trial

Already a subscriber? Click here to login

Hello! I'm Law360's automated support bot.

How can I help you today?

For example, you can type:
  • I forgot my password
  • I took a free trial but didn't get a verification email
  • How do I sign up for a newsletter?
Ask a question!